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Overexpression of efflux transporters, in human cells, is amechanism of resistance to drug and also to chemotherapy.We found that
multidrug resistance protein-4 (MRP4) overexpression has a role in reducing aspirin action in patients after bypass surgery and,
very recently, we found that aspirin enhances platelet MRP4 levels through peroxisome proliferator activated receptor-𝛼 (PPAR𝛼).
In the present paper, we verified whether exposure of human embryonic kidney-293 cells (Hek-293) to aspirinmodifiesMRP4 gene
expression and its correlation with drug elimination and cell toxicity. We first investigated the effect of high-dose aspirin in Hek-
293 and we showed that aspirin is able to increase cell toxicity dose-dependently. Furthermore, aspirin effects, induced at low dose,
already enhance MRP4 gene expression. Based on these findings, we compared cell viability in Hek-293, after high-dose aspirin
treatment, in MRP4 overexpressing cells, either after aspirin pretreatment or in MRP4 transfected cells; in both cases, a decrease of
selective aspirin cell growth inhibition was observed, in comparison with the control cultures. Altogether, these data suggest that
exposing cells to low nontoxic aspirin dosages can induce gene expression alterations that may lead to the efflux transporter protein
overexpression, thus increasing cellular detoxification of aspirin.
Dedicated to the memory of Alberto Gulino, an extraordinary and unforgettable mentor, who very recently passed away
1. Introduction
Exposure of eukaryotic cells to drugs can trigger modifica-
tions in the expression of mechanisms susceptible to favour
their elimination. In hepatocytes, this is most often related
to the transient induction of the transcriptional regulation of
genes by nuclear receptors [1–4].
Members of the ATP-binding cassette (ABC) transporter
superfamily are widely recognized as major contributors to
controlling drug distribution and pharmacokinetics and the
acquisition of anticancer drug resistance [5].
In cancer cells, efflux transporters’ overexpression is one
mechanism of resistance to chemotherapy [6, 7]. In vitro
exposure of cells for a prolonged period of time to anticancer
agents shows a correlation between increasing concentrations
of drugs and overexpression of transporters [3, 8].
This approach can be applied tomany other drugs to iden-
tify the transporter responsible for their efflux and responsi-
ble for resistance mechanism.
A member of the MRP/ABCC subfamily of ATP-binding
cassette transporters, which are capable of pumping a wide
variety of endogenous (including cyclic nucleotides) and
xenobiotic organic anionic compounds out of the cell, is
MRP4, which can be upregulated to reduce intracellular
organic anion toxicity or cholestasis [9].
We previously demonstrated that aspirin is a substrate for
MRP4 in human platelets [10], and it was confirmed that both
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aspirin and its salicylic acid (ASA) are substrates of mouse
ABCC4 (MRP4) [11].
One of our recent studies showed aspirin ability to influ-
ence megakaryocytic gene expression, leading to upregula-
tion ofMRP4 in human platelets through the activation of the
nuclear receptor PPAR𝛼 [12], suggesting that even aspirin can
activate mechanisms that favour its elimination and conse-
quently reduce its toxic effect.
Acute salicylate poisoning is a common medical emer-
gency, which carries a high mortality [13–15]. Salicylate
poisoning remains a clinically hazardous therapeutically
acquired intoxication at any age [16].
Aspirin poisoning is clearly dose related to increase toxic-
ity in human subjects [17]. Daily aspirin use, whether regular
strength or low dose, results in reduction in cancer incidence
and mortality, although potential side effect profiles must be
considered. It was suggested that one of the mechanisms by
which aspirin is chemopreventive for cancer is its capability of
inhibiting tumor cell proliferation [18]. In fact, aspirin toxicity
results from the perturbation of the cell cycle and ultimately
causes necrosis [19].
In this paper we showed that aspirin-dependent MRP4
overexpression effectively reduces the cytosolic concentra-
tion of aspirin in cells exposed to increasing concentrations
of this drug, providing a simple resistance mechanism.
We have now examined how human cells would respond
to stepwise exposure to increasing concentrations of drug
either in basal or in enhanced efflux protein transporter
expression (in the absence or in the presence of a detectable
efflux transporter). Indeed, we observed reduced aspirin
toxicity when the expression of MRP4 transporter is higher.
2. Material and Methods
2.1. Cell Line and Culture Conditions. Human embryonic
kidney-293 cells, Hek-293 cell line, were maintained in
DMEM supplemented with 10% heat-inactivated fetal bovine
serum, 20mM L-glutamine, 100 units/mL of penicillin G
sodium, and 100 𝜇g/mL streptomycin sulfate in a humidified
atmosphere containing 5% CO
2
at 37∘C. Cells were treated
with aspirin, either to induce MRP4 expression (50𝜇M for
48 h) or to induce cell death (5mM for 24 h) (SIGMAChem-
icals Company, St. Louis,MO) to study either gene expression
changes or aspirin toxicity, respectively. Control cells were
treated with vehicle.
2.2. DNA Constructs and Transfection. The PCDNA 3.1-
MRP4 vector expressing the human MRP4 protein was from
Dr. Rius et al. [20]. Cell transfection was performed as
previously described [21]; briefly, Hek-293 (1 × 106 cells plated
in 60mm dishes) cells were transfected with the indicated
amount (0.5𝜇g) of MRP4 expression vectors by TransFectin
Lipid Reagent (Bio-Rad Laboratories, Italy). An equivalent
amount of transfection reagent (TransFectin Lipid Reagent,
Bio-Rad), with PCDNA 3.1, was added as mock control. 24
hours after transfection, cells were treated with a high con-
centration of aspirin.
2.3. Cell Death Assay. In order to evaluate aspirin-dependent
toxicity, trypan blue assay and 7-AAD staining were per-
formed.
At the end of the treatment, cells were detached by tryp-
sinization and incubated with trypan blue and counted for
stained and unstained cells.
For FACS analysis, under different experiment condi-
tions, 1 × 106 cultured Hek-293 cells were freshly harvested
and incubated for 10 minutes in the dark with 5 𝜇L/test of 7-
AAD (BD Pharmingen) [21]. Within 1 h after dye incubation,
the cells were analysed on FACSscan (Becton Dickinson,
Mountain View, CA) using Cell Quest software (Becton
Dickinson).
2.4. High-Performance Liquid Chromatography Analysis.
Quantitative analysis of plasma concentrations of aspirin was
performed using HPLC according to Cerletti et al., 2003 [22].
Cells were washed twice with cold PBS, collected, and
centrifuged at 400 g for 10min. After extraction with hex-
ane (SIGMA Chemicals Company, St. Louis, MO), aspirin
was quantified by high-performance liquid chromatography
(HPLC) with ultraviolet detection at 229 nm. Aspirin con-
centration and peak-height ratios were linearly related up to
20𝜇g/mL. The lower limit of sensitivity was 0.1 𝜇g/mL. The
average recovery of aspirin was 27%.
2.5. Protein Extraction and Western Blot. In order to analyze
MRP4 protein, cells were washed twice with cold PBS, col-
lected, and centrifuged at 400 g for 10min. Cell pellets were
then resuspended in lysis buffer (RIPA buffer: 10mM Tris-
HCl (pH 7.6), 160mM NaCl, 1mM EGTA, 1% deoxycholic
acid, 1% Triton, and 0.1% SDS) with protease inhibitors,
incubated on ice for 30min, and centrifuged at 12,000 g for
30min; the supernatant was then collected.
Protein extracts (30𝜇g) were incubated at 37∘C for 30min
[20] and separated on 4–12% SDS-PAGE gel, blotted onto
PVDFmembrane (GEHealthcare, Milano, Italy), and probed
with rat anti-MRP4 (Alexis, Plymouth Meeting, Pennsyl-
vania) and mouse anti-actin (Santa Cruz Biotechnology,
Santa Cruz, CA) monoclonal antibodies. Immunoreactive
bands were visualized by enhanced chemoluminescence
(PerkinElmer, Waltham, MA, USA).
2.6. RNA Preparation and Real-Time PCR Analysis. Total
RNA from human cell lines was extracted using TRIzol
reagent (Invitrogen, San Diego, CA).
For mRNA detection 1𝜇g of total RNA was transcribed
using the GeneAmp Gold RNA PCR Reagent Kit pAW109
(Applied Biosystems, Warrington, UK) according to the
manufacturer’s suggestion.
The analysis of gene expression was carried out with
Q-RT-PCR using TaqMan Master Mix and TaqMan Assay
Reagents (Applied Biosystems, Warrington, UK).
The amplification, monitored using ABI Prism 7900
Sequencer Detector (Applied Biosystems, Foster City, CA),
was as follows: 50∘C for 2min, 95∘C for 10min, 95∘C for 15 sec,
and 60∘C for 1min; the latter two temperatures were repeated
for 40 cycles.
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Figure 1: Cells survival depends on the dose of aspirin. Cell survival
of either untreated or aspirin treated (from 0.5mM to 10mM) Hek-
293 cells for 24 hours. Trypan blue exclusion test analysis was used
to analyze cell death (“trypan blue-not excluding”). “Trypan blue-
not excluding” cell analysis is reported as percentage of dead cells,
in aspirin treated compared to untreated cells. Data are reported as
mean ± SD of 3 experiments performed.
All amplification reactions were performed in duplicate
using 25 ng of cDNA.
Changes in MRP4 and 𝛽-actin mRNA amounts were
quantified by using ΔΔCt method for relative quantization
of gene expression using SDS software version 2.3 (Applied
Biosystems, Warrington, UK).
2.7. Statistical Analysis. Data are presented as mean ± SD.
The level of significance was determined by paired, 2-tailed
Student’s 𝑡-test (KaleidaGraph software 3.6). Results were
considered statistically significant if a𝑃 value of less than 0.05
was reached.
3. Results
3.1. Influence of Aspirin on Cell Viability. As a preliminary
step in this work, we examined to what extent cells gone
through the process of selection by aspirin showed a distinct
pattern of viability compared to untreated cells (control).
Human embryonic kidney-293 cells (Hek-293) were incu-
bated with high concentrations of aspirin (from 0.5mM to
10mM, for 24 h) and then counted and subjected to trypan
blue assays (Figure 1). A dose-response analysis through cell
numeration showed that aspirin markedly reduced cell via-
bility, suggesting that high concentrations (0.5–10mM) of
aspirin have a toxic effect. This was demonstrated by trypan
blue assays; in fact, aspirin causes cell death in a dose-depend-
ent manner: 24 h treatment with high concentrations of this
drug was cytotoxic for a large proportion of Hek-293 cells,
while low concentrations were less effective (Figure 1).
3.2. MRP4 Expression in Aspirin Treated Hek-293 Cells. We
recently demonstrated that aspirin is a target for MRP4 and,
in in vitro treatment, it increases MRP4 expression [10, 12].
These studies suggest that MRP4 might be important for
aspirin outward transport by cells and for aspirin cell detoxi-
fication.
To confirm whether aspirin modulates MRP4 expression
in Hek-293 cells, we analyzed mRNA and protein expression
both in control and in aspirin treated cells.
Hek-293 cells treated with low-dose aspirin (50 𝜇M for
48 h) showed higher MRP4 mRNA levels compared to mock
culture (Figure 2(a)) suggesting a positive transcriptional
control.
In the same experimental conditions, western blot analy-
sis revealed an increase of MRP4 protein expression in cells
treated with aspirin (50𝜇M for 48 h) (Figure 2(b)).
Densitometry analysis showed a statistically significant
higher induction of MRP4 protein expression, which is
enhanced more than 30% in comparison with untreated cells
(Figure 2(c)).
Aspirin-dependent MRP4 overexpression may be impor-
tant to reduce drug cytosolic concentration, leading to
reduced aspirin toxicity.
3.3. Influence of High Concentrations of Aspirin on Control and
Aspirin-Pretreated Cells. Recent studies showed that eukary-
otic cells drug exposuremodulates expression ofmechanisms
favouring their elimination.
To study whether this mechanism is evident also after
aspirin treatment, Hek-293 cells were preincubated with
aspirin (50 𝜇M) and after 48 h they were treated with high
concentrations of aspirin (5mM for 24 h). After these incu-
bations, both control and pretreated cells were counted and
subjected to trypan blue dye exclusion and flow cytometry
(FACS) analysis with 7-AAD.
Trypan blue assay showed that, in cells directly treated
with 5mM aspirin for 24 h, cell viability was markedly
reduced in control cells, while it was almost unchanged in
comparison with 48 h aspirin pretreated cells (Figure 3(a)).
Interestingly, since staining with 7-AAD is more sensitive
to cellular damage, and to evaluate the effect, we performed
FACS analysis using 7-AAD, measuring the percentage of
dead cells with compromisedmembranes gating on thewhole
cell population (Figure 3(b)). As shown in the upper panels,
no differences in 7-AAD staining, before treatment, were
observed between control (6.8%) and pretreated cells (5.5%).
Instead, the lower panels of Figure 3(b) show an increase of
dead cells in response to high-dose aspirin (7-AAD+ cells)
in control cells (5-fold increase). On the other hand, in
aspirin pretreated cells (50 𝜇M for 48 h) still overexpressing
MRP4 (as shown in Figure 2(b)), a lower percentage of dead
cells (control 34.2% versus pretreated 13.0%) was observed
in response to high-dose aspirin. Moreover, we analyzed
the absolute number of 7-AAD positive over total cells, in
both control and pretreated cell samples. The results show
that the ratio of total numbers of 7-AAD positive cells in
aspirin (5mM) treated samples versus matched untreated
cells was reduced in a statistically significant way, when cells
were pretreated with low doses of aspirin (50𝜇M for 48 h)
(Figure 3(c)).
The data could suggest that aspirin is able to induce gene
expression changes, enhancing MRP4 expression in aspirin
pretreated cells, whichmight favour aspirin transport outside
the cells, leading to reduction of drug induced cell toxicity.
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Figure 2: Aspirin stimulates endogenous MRP4 mRNA and protein expression in Hek-293 cells. (a) Q-RT-PCR analysis of endogenous
MRP4 𝛼 expression after 48 h of treatment with 50𝜇M aspirin. Data were normalized with 𝛽-actin expression and reported as mean ± SD of
increasing fold, compared to control (𝑛 = 3). (b) Representative western blot, of 3 experiments performed, of endogenous MRP4 expression
after 48 h treatmentwith 50 𝜇Maspirin. Aspirin untreated cells were used as control cells. (c)Densitometric analysis of western blot is reported
as mean ± SD of increasing fold, compared to control (𝑛 = 3).
3.4. MRP4 Protects Hek-293 from Aspirin-Dependent Cyto-
toxicity. To confirm that MRP4 upregulation is responsible
for the reduced aspirin toxicity, we explored the effects of
exogenousMRP4 overexpression inHek-293 cells.These cells
were transfected either with pCDNA 3.1 (pCDNA 3.1), used
as a control, or with MRP4 expression vector (MRP4) and,
further, incubated for 24 h with high concentration of aspirin
(5mM). Afterwards, a comparative study of transfected cells,
with trypan blue dye assay and FACS analysis using 7-AAD
staining, was performed. The efficiency of the transfection
was monitored by western blot analysis confirming MRP4
protein overexpression in transfected cells (Figure 4(a)).
Trypan blue assay showed that cell viability was markedly
reduced in control cells when exposed to 5mM aspirin for
24 h, while it remains unchanged in MRP4 transfected cells
subjected to the same treatment (Figure 4(b)).
A comparative analysis by FACS of pCDNA 3.1 versus
MRP4 transfected cells was performed (Figure 4(c)). In
aspirin treated cells (5mM), the percentage of 7-AAD stained
cells was increased in pCDNA 3.1 transfected cells, rising
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Figure 3: Aspirin pretreatment is important for reduction of its toxicity. Cell death in Hek-293 cells, pretreated with 50 𝜇Mof aspirin (aspirin
pretreated cells) or with vehicle (control cells) for 48 h. In both conditions, toxicity was evaluated in untreated and aspirin treated (5mM) cells
24 h later. (a) Expression of “trypan blue-not excluding” cells is evaluated as percentage of dead cells in aspirin (5mM) treated cells compared
with control cells. Data were reported asmean ± SD of 3 experiments (NS: not significant). (b) Dead cell profile, representative flow cytometry
histograms of Hek-293 cells (1 × 106) stained with 7-AAD, out of three experiments performed. Left and right panels represent control and
aspirin pretreated cells, respectively. Percentages of 7-AAD+ cells are indicated in each panel. (c) Ratio of the total numbers of 7-AAD+ cells
in 5mM aspirin treated versus matched untreated cells, both in control and in aspirin pretreated cells. Data were reported as mean ± SD of 3
experiments performed; 𝑃 = 0.046 indicates significant differences in aspirin samples of control versus pretreated cells.
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Figure 4: Continued.
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Figure 4: MRP4 expression is relevant to reduce aspirin toxicity. Cell death in Hek-293 transfected cells (MRP4 cells). pCDNA3.1 transfected
cells were used as control (pCDNA3.1). Aspirin toxicity was evaluated after 24 h aspirin (5mM) treatment, with trypan blue exclusion test.
(a) Multidrug resistance protein-4 (anti-MRP4) expression in Hek-293 cell lines is shown in the first lane (PCDNA 3.1); MRP4 transfected
cultures are shown in the second lane (MRP4). A representative experiment, of 3 performed, is presented. (b) Expression of “trypan blue-
not excluding” cells is evaluated as percentage of cell death in aspirin treated cells (5mM) compared with control cells. Data were reported
as mean ± SD of 3 experiments performed (NS: not significant). (c) Dead cell profiles, representative flow cytometry histograms of Hek-
293 cells stained with 7-AAD, out of three performed experiments. The panel represents pCDNA3.1 and MRP4 transfected cells. Numbers
in histograms indicate percentage of 7-AAD+ cells. (d) Ratio of the total numbers of 7-AAD+ cells in 5mM aspirin treated versus matched
untreated cells, both in pCDNA3.1 and in MRP4 transfected cells. Data were reported as mean ± SD of 3 experiments performed; 𝑃 = 0.046
indicates significant differences in aspirin samples of pCDNA3.1 versus MRP4.
from 11.0% to 24.2%, while in MRP4 overexpressing cells the
percentage of 7-AAD stained cells (7-AAD+ cells) was slightly
enhanced (from 8.6% to 11.0%).
Under aspirin treatment (5mM), the ratio of total num-
bers of 7-AAD positive cells in MRP4 versus matched
pCDNA3.1 transfected cells was decreased, as observed in
three experiments performed (Figure 4(d)).
Altogether, these data support the hypothesis that MRP4
overexpression is important to reduce aspirin-selective cell
death. The protective effect may depend on the MRP4-
induced aspirin extrusion from the cell.
3.5. Accumulation of Aspirin in Control andMRP4 Transfected
Cells. To analyze whether MRP4 is able to modulate aspirin
transport outside the cell, we compared intracellular accumu-
lation of aspirin in MRP4 versus pCDNA 3.1 transfected cells
both treated with 5mM aspirin for 24 h.
After such treatment, we analyzed cytosolic aspirin accu-
mulation using a selective and sensitive method. As shown in
Figure 5, aspirin accumulation is reduced, about 2 times less,
inMRP4 transfected compared to pCDNA3.1 cells (Figure 5).
These data demonstrate an inverse correlation between trans-
porter and intracellular substrate level, since very highMRP4
expression is directly related to a reduced intracellular aspirin
concentration.
4. Discussion
Many reports outlined a close correlation between increased
MRP transporters expression and impairment of pharmaco-
logical treatment.
In the present study, we have shown that exposure of
eukaryotic cells to aspirin, anMRP4 target [10, 11], can deeply
modify the expression of this efflux transport protein, in a
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Figure 5: A reduced aspirin cytoplasmatic concentration in MRP4
transfected Hek-293 cells. Percentage of aspirin cytoplasmatic con-
centration inMRP4 transfected cells (MRP4) after aspirin treatment
(5mM for 24 h) in comparison with those found in control cells
(pCDNA 3.1). The results are expressed as mean ± SD of 3
experiments performed.
human cell line, Hek-293. Our results suggest that such mod-
ifications can result in enhanced aspirin transport outside the
cells, leading to a reduction of the toxic effect of this drug.
Such relationship between drug toxicity and MRP4
upregulation is already reported inmouse. In fact, after in vivo
perfluorooctanoic acid and perfluorodecanoic acid admin-
istration, liver mounts a compensatory hepatoprotective
response, leading to a marked increase of MRP4 expression
[23], in order to reduce drug toxicity.
As aspirin toxicity results in the perturbation of the cell
cycle and ultimately causes necrosis [19], we investigated,
first, through a dose-response curve, the effect of high-dose
aspirin treatment, and we showed that aspirin is able to
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increase cell death in Hek-293 cell line, at similar concentra-
tions to those found by others [19].
In our recent study, we showed that also aspirin is able
to modulate MRP4 expression in human platelets, and we
speculated that the limited drug capacity in reducing platelet
function, observed in aspirin long-term treated patients [24],
could be due to a drug-dependent MRP4 upregulation [12].
Aspirin influences megakaryocytic gene expression leading
to upregulation of MRP4 in human platelets, suggesting
that even aspirin can activate mechanisms that favour its
elimination, thus consequently reducing its toxic effect [12].
In agreement with this previous report, aspirin-depend-
ent MRP4 upregulation was confirmed also in Hek-293 cells,
widening the spectrum of the cells subjected to this mech-
anism. In fact, aspirin treatment increases MRP4 mRNA
and protein expression levels for 48 hours in Hek-293 cells.
This upregulation induced also by low nontoxic aspirin
dosage can be important to regulate aspirin effect. Indeed,
pretreatment with low doses of aspirin reduces its toxicity by
decreasing the percentage and absolute numbers of nonviable
cells, suggesting the induction of a protective mechanism.
We cannot exclude the contribution of a mechanism of cell
selection operated by aspirin. This may affect drug intended
and drug side effects in many tissue districts since MRP4 is
ubiquitously expressed, including hematopoietic cells [25].
Furthermore, modulation of aspirin effects may be important
in long-term daily aspirin use.
Several studies show that acute salicylate poisoning is a
common medical emergency which leads to a high mortality
[13–15] and aspirin poisoning is clearly dose related in order
to increase toxicity in human subjects [17].
The direct connection between aspirin-induced MRP4
expression and cell toxicity was further addressed by over-
expressing MRP4 extruding protein in our cell line. Indeed,
MRP4 high levels are well correlated with reduced num-
bers of 7-AAD positive cells. In this study we demonstrate
that aspirin-dependent MRP4 upregulation is important to
reduce intracellular aspirin concentration, by enhancing its
transport. In fact, MRP4 overexpression leads to cells drug
detoxification in a more efficient manner in human Hek-293.
To confirm that MRP4 is the aspirin transporter involved
in such phenomenon, we compared cellular accumulation
of aspirin in MRP4 transfected cells versus control cells
treated with aspirin (5mM for 24 h). Indeed, aspirin showed
a reduced cytosolic accumulation in MRP4 transfected com-
pared to control cells.
Our data support the evidence that aspirin-dependent
overexpression of MRP4 is a cell adaptation to what seems
to be a major toxic stress [26].
With our results, we can also suggest that, in the future, it
should be important to study a possible correlation between
the treatment with aspirin and that with chemotherapeutic
agents, in order to verify drug efficiency.
5. Conclusion
In conclusion, this study demonstrates that aspirin, at low
nontoxic drug dosage, is able to activate a positive tran-
scriptional control of the MRP4/ABCC4 transporter gene, in
human cells, thus enhancing the activity of the mechanism
susceptible to increase aspirin efflux.
We speculate that our data are suggestive of the ability of
low-dose aspirin to confer clinical drug resistance, particu-
larly in long-term treated patients.
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